选择性5-羟色胺再摄取抑制剂联合丙戊酸钠缓释剂治疗伴激越、焦虑抑郁症的临床观察

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (1): 86-89.

选择性5-羟色胺再摄取抑制剂联合丙戊酸钠缓释剂治疗伴激越、焦虑抑郁症的临床观察

谢建平¹, 任志斌², 马永春², 唐建良³, 金卫东²

¹浙江省桐乡市第三人民医院精神科,桐乡 314501,浙江;
²浙江中医药大学附属同德医院,浙江省立同德医院,浙江省精神卫生中心,杭州 310012,浙江;
³浙江省嘉兴康慈医院,嘉兴 314500,浙江

收稿日期:2012-08-20 修回日期:2012-08-20 发布日期:2013-02-05
作者简介:谢建平,男,本科,副主任医师,研究方向:临床精神病学。 Tel: 13819399811 E-mail: kcyyxjp@163.com

Comparing study on therapeutic of outpatients with agitated or anxiety depression by combination of SSRI and sodium valproate RX

XIE JIAN-ping¹, REN Zhi-bin², MA Yong-chun², TANG Jian-liang³, JIN Wei-dong²

¹Department of Psychiatry, Tongxiang 3nd Hospital of Zhejiang Province,Tongxiang 314501,Zhejiang,China;
²Department of Psychiatry, Zhejiang Province Tongde Hospital, Zhejiang Province Mental Health Center,Hangzhou 310012, Zhejiang,China;
³Department of Psychiatry, Jiaxing Kangci Hospital of Zhejiang Province, Jiaxing 314500, Zhejiang,China

Received:2012-08-20 Revised:2012-08-20 Published:2013-02-05

摘要/Abstract

摘要： 目的: 观察选择性5-羟色胺再摄取抑制剂(SSRI)联合应用丙戊酸钠缓释剂治疗伴有激越、焦虑症状抑郁症的疗效及安全性。方法: 80例符合抑郁症诊断标准同时伴有激越症状、焦虑症状患者随机分为研究组(在SSRI的基础上联合丙戊酸钠缓释剂)和对照组(仅仅使用SSRI),每组40例。分别于治疗前、治疗后1、2、4、8周使用汉密尔顿抑郁评定量表(HAMD)、汉密尔顿焦虑评定量表(HAMA)、杨氏躁狂量表(YMRS)、副反应量表(TESS)评价疗效和不良反应。结果: 研究组有2例失访脱落,治疗后1、2、4、8周的有效率和痊愈率分别是 28.9%(11/38)与 7.9%(3/38)、36.8%(14/38)与 13.2%(5/38)、50%(19/38)与 28.9%(11/38)、89.5%(34/38)与 52.6%(20/38)。对照组因副作用3例脱落、其中1例因转躁退出,治疗后1、2、4、8周的有效率和痊愈率分别是 21.6%(8/37)与 5.4%(2/37)、32.4%(12/37)与 8.1%(3/37)、43.2%(16/37)与 18.9%(7/37)、54.1%(20/37)与 32.4%(12/37)。两组治疗后1、2、4、8周末HAMD、HAMA、YMRS评分,与治疗前相比均有统计学差异(P<0.01)。对照组从治疗后第1周到第8周,各时点的3个量表评分均高于研究组,差异有统计学意义( P<0.05 或 0.01)。不良反应总体发生数两组间比较无统计学差异(P>0.05)。结论: 丙戊酸钠缓释剂联合SSRI治疗某些伴有激越、焦虑症状的抑郁症疗效优于单一使用SSRI,且安全性较高。

关键词: 激越性抑郁, 焦虑, 选择性5-羟色胺再摄取抑制剂, 丙戊酸钠缓释剂

Abstract: AIM: To observe the efficacy and safety of selective serotonin reuptake inhibitors (SSRI) collaborating with Sodium Valproate RX on the treatment of depression with agitation or anxiety. METHODS: Totally 80 cases which conform to the diagnostic criteria of depression with agitation or anxiety were randomly divided into the treatment group (using SSRI collaborating with Sodium Valproate RX) and the control group (only using SSRI), each group had 40 cases. The efficacy and safety were assessed by Hamilton Depression Rating Scale (HAMD), Hamilton anxiety rating scale (HAMA), Young Mania Rating Scale (YMRS) and Treatment Emergent Side-Effect Scale (TESS) at pretreated, 1-week, 2-week, 4-week and 8-week after treatment. RESULTS: 2 cases dropout for lost in 40 cases of the treatment group. The effective rate and full remission rate were 28.9%(11/38)and 7.9%(3/38),36.8%(14/38)and 13.2%(5/38),50%(19/38)and 28.9%(11/38),89.5%(34/38)and 52.6%(20/38) at 1-week, 2-week, 4-week and 8-week after treatment in treatment group . Meanwhile 3 cases dropout in 40 cases of the control group for side reactions (1 for swiching to mania ). The effective rate and full remission rate were 21.6%(8/37)and 5.4%(2/37),32.4%(12/37)and 8.1%(3/37),43.2%(16/37)and 18.9%(7/37),54.1%(20/37)and 32.4%(12/37)at 1-week, 2-week, 4-week and 8-week after treatment in control group. Compared with before treatment, the levels of HAMD,HAMA,YMRS had significant difference at 1-week, 2-week, 4-week and 8-week after treatment in two groups (P<0.01).There was no significant difference of the overall number of adverse reaction between the two groups (P>0.05). CONCLUSION: The combination of SSRI and Sodium Valproate RX maybe one of better ways in the treatment of depression.with agitation or anxiety for their better efficacy and higher safety than the sole using of SSRI.

Key words: Agitated Depression, Anxiety, Selective serotonin reuptake inhibitors (SSRI), Sodium Valproate RX

中图分类号:

R749

谢建平, 任志斌, 马永春, 唐建良, 金卫东. 选择性5-羟色胺再摄取抑制剂联合丙戊酸钠缓释剂治疗伴激越、焦虑抑郁症的临床观察[J]. 中国临床药理学与治疗学, 2013, 18(1): 86-89.

XIE JIAN-ping, REN Zhi-bin, MA Yong-chun, TANG Jian-liang, JIN Wei-dong. Comparing study on therapeutic of outpatients with agitated or anxiety depression by combination of SSRI and sodium valproate RX[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 86-89.

[1]	吴雄志, 王宣, 徐四七, 居霞, 王胜斌, 陈永权. 咪达唑仑口服溶液比右美托咪定喷鼻更有效缓解儿童术前焦虑[J]. 中国临床药理学与治疗学, 2023, 28(6): 666-670.
[2]	丁露露，郭建友. 特质焦虑的神经生物学因素及其对个体认知表现的影响[J]. 中国临床药理学与治疗学, 2020, 25(1): 101-106.
[3]	林敏，沈仲夏，钱敏才，崔力军，任列，蔡敏，沈鑫华. 5-羟色胺转运体基因多态性与抗抑郁剂治疗广泛性焦虑障碍疗效的关联[J]. 中国临床药理学与治疗学, 2019, 24(8): 903-909.
[4]	周严灿. 阿戈美拉汀治疗抑郁障碍的疗效及对脑源性神经营养因子的影响[J]. 中国临床药理学与治疗学, 2019, 24(6): 699-703.
[5]	蔡丹丹, 桂冬辉, 张建兵, 周文华. 小剂量利培酮联合曲唑酮应用于海洛因成瘾脱毒期的疗效分析[J]. 中国临床药理学与治疗学, 2019, 24(1): 94-98.
[6]	常永丽，王春雷，原丽，郭晓姝，韩玲娜. 外侧隔GABA_A受体在帕金森病模型大鼠焦虑样行为中的作用[J]. 中国临床药理学与治疗学, 2018, 23(7): 734-742.
[7]	龚晓兵，李淑珍，黄叶盛，马彦，柳永刚，蒋亚斌，杨见权. 坦度螺酮治疗伴有焦虑抑郁的功能性消化不良的疗效及对生存质量的影响[J]. 中国临床药理学与治疗学, 2017, 22(6): 664-667.
[8]	徐道祥，史惠敏，林小东. 盐酸帕罗西汀联合丹栀逍遥丸治疗抑郁症伴焦虑的临床对照研究[J]. 中国临床药理学与治疗学, 2017, 22(3): 321-325.
[9]	杨琴，杜青，赵洪庆，王宇红，韩远山，杨蕙，孟盼 . 百合疏肝安神汤对焦虑性抑郁症模型大鼠前额叶-边缘结构及GR/BDNF/NPY表达的影响[J]. 中国临床药理学与治疗学, 2017, 22(10): 1090-1098.
[10]	刘晓萍，赖香茂，王海全，陈玉梅，张冬梅. 药物整合在慢性阻塞性肺疾病合并焦虑抑郁障碍患者中的应用价值[J]. 中国临床药理学与治疗学, 2016, 21(9): 1038-1041.
[11]	刘悦, 沈雯雯, 黄燕燕, 张建兵, 周文华. 曲唑酮联合心理治疗对海洛因依赖者脱毒期的疗效观察[J]. 中国临床药理学与治疗学, 2015, 20(5): 578-582.
[12]	王晓倩，郭风莲，沈伶俐，林勇. 度洛西汀联合认知治疗对慢性盆腔疼痛伴发焦虑、抑郁的对照研究[J]. 中国临床药理学与治疗学, 2015, 20(12): 1418-1422.
[13]	叶夷露，徐佳妮，吴丽君，刘丹丹，张琦，吕圭源. 黄连解毒汤对mCPP诱导焦虑样行为的作用研究[J]. 中国临床药理学与治疗学, 2015, 20(11): 1227-1232.
[14]	沈仲夏,沈鑫华,蔡敏,方瑜,林敏,杨剑虹,许毅. 艾司西酞普兰快速剂量滴定治疗广泛性焦虑障碍的对照研究[J]. 中国临床药理学与治疗学, 2014, 19(11): 1263-1267.
[15]	李亚玲, 叶建飞, 李婷, 李国荣. 右佐匹克隆合并艾司西肽普兰治疗广泛性焦虑伴失眠的对照研究[J]. 中国临床药理学与治疗学, 2014, 19(1): 54-57.